secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2024-09-09T23:59:59+00:00
Accession:  0001140361-24-040507
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant/Immunovant: Phase 2a batoclimab 76% response in GD; pivotal IMVT-1402 trial by year end
--------------------------------------------------------------------------------

- High-dose batoclimab (680mg SC weekly) achieved 76% response rate and 56% ATD-free response in uncontrolled GD at week 12.
- Mean IgG reduction of 77% correlated with clinical outcomes; ≥70% IgG reduction yielded 60% ATD-free response vs 23%.
- FDA cleared IND for IMVT-1402; pivotal trial in Graves' Disease expected to initiate by December 31, 2024.
- Real-world data shows 25-30% of GD patients per year are uncontrolled on ATDs, representing a large commercial opportunity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124040507/0001140361-24-040507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124040507/ef20035648_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-040507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer